Compare · AZN vs REVB
AZN vs REVB
Side-by-side comparison of AstraZeneca PLC (AZN) and Revelation Biosciences Inc. (REVB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and REVB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 66047.9x REVB ($4.0M).
- AZN has been more active in the news (14 items in the past 4 weeks vs 12 for REVB).
- AZN has more recent analyst coverage (25 ratings vs 1 for REVB).
- Company
- AstraZeneca PLC
- Revelation Biosciences Inc.
- Price
- -
- -
- Market cap
- $263.10B
- $4.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 14
- 12
- Recent ratings
- 25
- 1
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Revelation Biosciences Inc.
Revelation Biosciences, Inc., a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis. Its lead diagnostic is the REVDx -501, a rapid test kit to detect various respiratory viral infections. The company also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination. Revelation Biosciences, Inc. was founded in 2019 and is headquartered in San Diego, California.
Latest AZN
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Latest REVB
- Revelation Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
- Chief Financial Officer Zygmont Chester Stanley Iii was granted 208,073 shares, gifted 208,073 shares and received a gift of 208,073 shares (SEC Form 4)
- Director Chawla Lakhmir S was granted 32,011 shares, increasing direct ownership by 263% to 44,169 units (SEC Form 4)
- Director Roper Jess was granted 32,011 shares, increasing direct ownership by 250% to 44,839 units (SEC Form 4)
- Chief Executive Officer Rolke James was granted 208,076 shares, increasing direct ownership by 97% to 422,814 units (SEC Form 4)
- Director Carver Jennifer was granted 32,011 shares, increasing direct ownership by 251% to 44,769 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Revelation Biosciences Inc.
- Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026